BridgeBio Pharma

BBIO

Biotechnology · Healthcare

Price

$81.50

-1.44 (-1.74%)

Market Cap

$15.96B

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+36.6% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 144.4M (2021) → 197.2M (2025)

Winston Score History

The full picture

BridgeBio Pharma is a biotechnology company that discovers and develops medicines for genetic diseases — illnesses caused by errors in a person's DNA. Its main approved drug is acoramidis (sold as Attruby), a treatment for a rare and serious heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM), where a misfolded protein builds up and damages the heart. The company focuses on patients with few or no other treatment options.

BridgeBio earns money primarily through drug sales, with Attruby launched in the US in early 2025 and competing directly against Pfizer's tafamidis in a growing market. The company operates mainly in the United States and is still spending heavily on research, which explains its deeply negative operating margin despite a very high gross margin on the drugs it does sell. The key growth driver is how quickly Attruby can capture market share from tafamidis, but the main risk is that commercial uptake could disappoint, and the company still burns significant cash.

Politician Trades

7 trades / 12mo

7 Congressional buys and 0 sells on BBIO in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+101.2% YoY

YoY Growth Rate

Strong revenue growth

EPS Growth

+17.9% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

$478M/ year

↓ Declining (-6% vs prior year)

95.1% of revenue

5.3x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

13.6%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~10 months

$775M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Strong grower

BridgeBio Pharma is growing revenue at 101% year-over-year. The Winston Score penalises unprofitable companies, but revenue at this pace tells a different story — this is a company still in "build mode."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

93.2%

Premium pricing power — 93.2% gross margin

Profit after running costs

Operating Margin

-48.1%

Losing money on operations — -48.1%

Return on the money invested

ROCE

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+193.4%

Fast-growing sales (+193.4% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-85.6%

Burning cash (-85.6%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

—

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial